Clinical Trial

Clinical Study to Assess the Efficacy and Safety of Olaparib in Chinese Patients With Metastatic Castration-Resistant Prostate Cancer Who Have Failed Prior Treatment With a New Hormonal Agent and Have BRCA1/2 Mutations

Active, Not Recruiting Phase 4
View on ClinicalTrials.gov →
Summary
The purpose of this study is to evaluate the efficacy and safety of Olaparib compared with standard of care (Enzalutamide or Abiraterone Acetate) in Chinese men with metastatic castration-resistant prostate cancer who have failed prior treatment with a new hormonal agent and have BRCA1/2 mutations.
Protocol Amendment History 28 amendments
This ClinicalTrials.gov record has been amended 28 times since 2022-07-11; most recent amendment 2026-03-31.
Status change: Completed → Active, Not Recruiting 2026-03-31
Status change: Active, Not Recruiting → Completed 2025-12-05
Status change: Recruiting → Active, Not Recruiting 2024-01-24
Status change: Not Yet Recruiting → Recruiting 2022-08-05
Trial Details
NCT Number NCT05457257
Lead Sponsor AstraZeneca
Collaborators: Merck Sharp & Dohme LLC, Foundation Medicine, Myriad Genetics, Inc.
Conditions Metastatic Castration-resistant Prostate Cancer
Enrollment 43 participants
Start Date 2022-07-29
Primary Completion 2024-10-22 (estimated)
Study Completion 2026-12-31 (estimated)
Updated on ClinicalTrials.gov 2026-04-21